Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence
Abstract
The goal of this study is to determine whether dose-intensive adjuvant regimens for breast cancer induce genetic damage to hematopoietic stem cells, defined by the emergence of clonal hematopoiesis. Two different assays are used to detect clonality: the HUMARA (human androgen receptor) assay to estimate the incidence of early genetic damage defined by the presence of clonal hematopoiesis and microsatellite instability testing to screen for loss of heterozygosity or the presence of defective DNA mismatch repair mechanisms. Study accomplishments to date include: (a) SWOG protocol (S9719) activation, (b) centralized specimen collection! processing repository developed, (c) clonality assays developed/standardized, (d) specimen collection/data analysis of 68 samples from 14 patients completed, (e) DoD submission of protocol amendments to increase patient accrual by incorporating S9719 into the clinical treatment (S9623) protocol, and (f) presentation of biannual 59719 protocol updates at SWOG group meetings. Analysis of additional patients with longer follow-up is essential to confirm these preliminary results; however, at this point, neither regimen used in this setting (dose-intensive therapy with growth factor support vs high-dose therapy with stem cell reinfusion for stage II/III breast cancer) appears to initiate genetic damage that could result in development of hematologic malignancies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1999
- Accession Number
- ADA378125
Entities
People
- Charles A. Coltman Jr.